Related Experiment Video
Updated: Aug 4, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
[Effects of RelA antisense oligonucleotide on apoptosis of ovarian cancer cells COC1]
Changyu Wang1, Fang Hu, Yunping Lu
1Department of Obstetrics and Gynecology, Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University, Wuhan, 430030, China.
Objective:
To evaluate the effects of RelA antisense oligonucleotide on apoptosis of ovarian cancer cells.
Methods:
COC1 cell line was treated with RelA antisense oligonucleotide combining with tumor necrosis factor (TNF)-alpha or paclitaxel at appropriate concentrations and duration. The apoptosis and RelA activation of ovarian cancer line COC1 cell were measured by indirect immunofluorescence, Western blot, flow cytometric analysis, DNA ladder assay.
Results:
The apoptosis increased obviously in COC1 rells if treated by RelA antisense oligonucleotide combining with paclitaxel 50 micromol/L than paclitaxel 50 micromol/L only (27.4 +/- 0.5)% vs (12.3 +/- 0.6)% (P < 0.01), when treated 12 hs; (31.7 +/- 0.3)% vs (13.0 +/- 0.5)% (P < 0.01) when treated 24 hs. The apoptosis was also increased obviously in COC1 cells if treated by RelA antisense oligonucleotide combining with TNF-alpha 50 microgram/L than TNF-alpha 50 microgram/L alone. (30.8 +/- 0.3)% vs (13.2 +/- 0.4)% (P < 0.01).
Conclusion:
RelA antisense oligonucleotide may induce apoptosis susceptibility of COC1 cells to TNF-alpha or paclitaxel.
Insights
RelA antisense oligonucleotide enhances ovarian cancer cell apoptosis when combined with paclitaxel or tumor necrosis factor-alpha (TNF-alpha). This suggests a potential therapeutic strategy for ovarian cancer treatment.
Area of Science:
- Molecular biology
- Cancer research
- Ovarian cancer cell line studies
Context:
- Ovarian cancer remains a significant health challenge.
- Developing novel therapeutic strategies is crucial.
- Understanding apoptosis pathways is key to cancer treatment.
Purpose:
- To investigate the effect of RelA antisense oligonucleotide on ovarian cancer cell apoptosis.
- To determine if RelA antisense oligonucleotide sensitizes cells to chemotherapy and immunotherapy.
Summary:
- COC1 ovarian cancer cells were treated with RelA antisense oligonucleotide alongside paclitaxel or TNF-alpha.
- Apoptosis levels were significantly increased when RelA antisense oligonucleotide was combined with either agent compared to agents alone.
- RelA activation was also assessed using various laboratory techniques.
Impact:
- RelA antisense oligonucleotide may enhance the efficacy of existing ovarian cancer treatments.
- This finding opens avenues for developing targeted therapies that increase apoptosis susceptibility.
- Further research could explore clinical applications of this approach.
More Related Videos
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
09:40Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
